Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness
Verified: 10 outlets in 7 countries have reported this story since Nov 9, 2 of them from the United States.
There is no known treatment to reverse vision loss caused by NAION. It is the most common cause of acute optic nerve injury in people over 50 years old, according to the academy.
⚠ A state-run outlet: it may reflect official government positions.
How sure are we
Two or more outlets reported this story and its reliability score reached 65%, so WorldPulse marks it verified. That means more than one outlet says so, not that it is proven true.
Who reported it
2 outlets from the United States, where the story is: Ars Technica, STAT News · how we count
- Nov 9, 4:19 PM UTCFirst reportSTAT+: FDA warns GLP-1 drugs carry potential risk of rare eye conditionstatnews.com ↗
- Nov 9, 4:47 PM UTC+28 minFDA requires vision-loss warning on Novo Nordisk and Eli Lilly GLP-1 drugsinvesting.com ↗
- Nov 9, 9:58 PM UTC+6 hFDA adds rare vision-loss warning to popular GLP-1 weight loss drugsjamaica-gleaner.com ↗
- Nov 10, 8:21 PM UTC+28 hMakers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindnessbbc.co.uk ↗
- Nov 10, 8:42 PM UTC+28 hFDA warns of rare eye condition causing blindness from GLP-1 weight loss medicationstheguardian.com ↗
- Nov 10, 8:44 PM UTC+28 hFDA warns of rare eye condition causing blindness from GLP-1 weight loss medicationstheguardian.com (again) ↗
- Nov 11, 9:19 AM UTC+41 h· you’re reading thisMakers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindnesskbc.co.ke ↗
[Claude] All three other reports cover the same FDA order requiring NAION warnings on GLP-1 drug labels and do not contradict Report 1's facts.
42m agoScore bands
What moves the score
Not in the score: AI checks and reader flags. Verified is separate: two or more independent outlets and a score of at least 65%.
High · How we score this